These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Moschella F; Proietti E; Capone I; Belardelli F Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466 [TBL] [Abstract][Full Text] [Related]
43. Immunobiology of carcinoma of the prostate. Catalona WJ Invest Urol; 1980 Mar; 17(5):373-7. PubMed ID: 6987190 [TBL] [Abstract][Full Text] [Related]
44. Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Dong B; Minze LJ; Xue W; Chen W Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804 [TBL] [Abstract][Full Text] [Related]
45. Current aspects of tumor immunology. Preface and introduction. Weiss DW Isr J Med Sci; 1973 Mar; 9(3):205-16. PubMed ID: 4575649 [No Abstract] [Full Text] [Related]
47. [Antitumor immunotherapy]. Błoński JZ; Warzocha K Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731 [TBL] [Abstract][Full Text] [Related]
48. Lung cancer immunotherapy. Raez LE; Fein S; Podack ER Clin Med Res; 2005 Nov; 3(4):221-8. PubMed ID: 16303887 [TBL] [Abstract][Full Text] [Related]
49. Specific and non-specific responses in host resistance to tumors. Baldwin RW Tokai J Exp Clin Med; 1983 Dec; 8(5-6):419-28. PubMed ID: 6398929 [TBL] [Abstract][Full Text] [Related]
50. BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Guinan PD; John T; Nagale V; Ablin RJ Allergol Immunopathol (Madr); 1978; 6(4):293-6. PubMed ID: 735980 [TBL] [Abstract][Full Text] [Related]
51. New possibilities for cancer therapy with advances in cancer immunology. MacLean GD; Longenecker BM Can J Oncol; 1994 Apr; 4(2):249-54. PubMed ID: 7516257 [TBL] [Abstract][Full Text] [Related]
52. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802 [TBL] [Abstract][Full Text] [Related]
53. Cancer vaccines: reborn or just recycled? Berd D Semin Oncol; 1998 Dec; 25(6):605-10. PubMed ID: 9865675 [TBL] [Abstract][Full Text] [Related]
54. Prostate carcinoma: immunostaging and adjuvant immunotherapy with BCG. Guinan PD; John T; Sahadevan V; Crispen R; Nagale V; McKiel C; Ablin RJ Natl Cancer Inst Monogr; 1978 Dec; (49):355-60. PubMed ID: 748793 [TBL] [Abstract][Full Text] [Related]
55. [Cancer immunotherapy: immunologic bases, reality and hopes]. Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939 [TBL] [Abstract][Full Text] [Related]
56. Biologic and immunologic therapy of ovarian cancer. Bookman MA; Berek JS Hematol Oncol Clin North Am; 1992 Aug; 6(4):941-65. PubMed ID: 1500395 [TBL] [Abstract][Full Text] [Related]
58. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer. Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945 [No Abstract] [Full Text] [Related]